MiMedx Group, Inc. announced on May 5, 2025, the publication of health economics data for its EPIFIX product in the May 2025 issue of the Journal of Drugs in Dermatology. The study focused on the reconstruction of cutaneous wounds following Mohs micrographic surgery (MMS).
The retrospective analysis of 429 Mohs patients demonstrated that EPIFIX significantly reduced adverse post-repair sequelae, with 97.2% of patients experiencing no complications compared to 78.7% with traditional methods. Patients treated with placental tissue also achieved wound closure faster, averaging 33.3 days versus 48.3 days for autologous tissue repairs.
This data highlights EPIFIX's ability to provide a cost-effective alternative in high-risk surgeries by minimizing postoperative complications and reducing the need for additional procedures. The findings are expected to inform clinicians and health policy makers about the benefits of innovative approaches in the Mohs surgery market, which sees over 850,000 procedures annually in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.